The importance of patient-specific dose calculations in nuclear medicine

Nuclear Engineering and Technology

Volumn 40, Issue 7, 2008, Pages 527-532

  Stabin, Michael G ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Nuclear medicine; Patient safety; Radiation dosimetry; Therapy

Indexed keywords

EID: 58149242515     PISSN: 17385733     EISSN: None     Source Type: Journal    
DOI: 10.5516/NET.2008.40.7.527     Document Type: Article

References (36)

1. M.G. Stabin Internal Radiation Dosimetry. Nuclear Medicine, 2nd Ed., Vol 1, Chapter 22, 313-331, edited by RE Henkin, D Bova, GL Dillahay, JR Halema, SM Karesh, RH Wagner, AM Zimmer. Mosby, St. Louis, MO (2006).
2. M.G. Stabin, R. Blackwell, R.L. Brent, E. Donnelly, V.A. King, K. Lovins, M. Stovall. Fetal Radiation Dose Calculations. ANSI N13.54-2008, American National Standards Institute, Washington, DC (2008).
3. International Commission on Radiological Protection. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals, 53, Pergamon, New York (1989).
4. International Commission on Radiological Protection. Radiation Dose To Patients From Radiopharmaceuticals. ICRP Publication 80, Pergamon, New York (2000).
5. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and Effects of Ionizing Radiation. UNSCEAR 2000 Report to the General Assembly, United Nations Scientific Committee on the Effects of Atomic Radiation (2000).
6. C. Canzi, F. Zito, F. Voltini, E. Reschini, P. Gerundini. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Medical Physics 33(8) 2860-2867 (2006).
7. T. Carlier, P.Y. Salaun, M.B. Cavarec, F. Valette, A. Turzo, M. Bardies, Y. Bizais, O. Couturier. Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic I-131 activity. Nuclear Medicine Communications 27(7) 559-566 (2006).
8. E. E. Furhang, S. M. Larson, P. Buranapong, J. L. Humm. "Thyroid cancer dosimetry using clearance fitting", Journal of Nuclear Medicine, 40(1):131-136 (1999).
9. H. R. Maxon, S. R. Thomas, R. C. Samaratunga. "Dosimetric considerations in the radimodine treatment of macrometastases and micrometastases from differentiated thyroid cancer", Thyroid, 7(2):183-187,(1997).
10. C. Kobe, W. Eschner, F. Sudbrock, I. Weber, K. Marx, M. Dietlein, H. Schicha. "Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy" Nuklearmedizin, 47:14, (2007).
11. C. A- Hoefnagel. "Nuclear medicine therapy of neuroblastoma", Quarterly Journal of Nuclear Medicine, 43 (4):336-343 (1999).
12. K. K. Matthay, C. Panina, J. Huberty, D. Price, D. V. Glidden, H. R. Tang, R. A. Hawkins, J. Veatch, B. Hasegawa. "Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma. treated with I-131-MIBG", Journal of Nuclear Medicine, 42(11):1713-1721 (2001).
13. M. N. Gaze, Y. C. Chang, G. D. Flux, R. J. Mairs, F. H. Saran, S. T. Meller. "Feasibility of dosimetry-based highdose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma", Cancer Biotherapy and Radiopharmaceuticals, 20(2):195-199 (2005).
14. R. L. Wahl, S. Kroll, K. R. Zasadny. "Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation", Journal of Nuclear Medicine, 39(8):14S-20S (1998).
15. G. A. Wiseman, C. A. White, R. B. Sparks, W. D. Erwin, D. A. Podoloff, D. Lamonica, N. L. Bartlett, J. A. Parker, W. L. Dunn, S. M. Spies, R. Belanger, T. E. Witzig, B. R. Leigh. "Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin's lymphoma", Critical Reviews in Oncology Hematology, 39(1-2):181-194 (2001).
16. M. Cremonesi, M. Ferrari, M. Chinol, M. Bartolomei, M.G. Stabin, E. Sacco, M. Fiorenza, G. Tosi, G. Paganelli. "Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience", Quarterly Journal of Nuclear Medicine, vol. 44, no. 4, pp. 325-332, 2000
17. Barone R., Walrand S., Valkema R., Kvols L., Smith C., Krenning E. P., Jamar F., & Pauwels S. "Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy", Journal ofNuclear Medicine, 43(5):1267 (2002).
18. M.G. Stabin The Case for Patient-Specific Dosimetry in Radionuclide Therapy. Cancer Biotherapy & Radiopharmaceuticals, 23 (3): 273-284 (2008).
19. M.G. Stabin and J. A. Siegel. Physical Models and Dose Factors for Use in Internal Dose Assessment. Health Physics, 85(3):294-310 (2003).
20. W. Snyder, M. Ford, G. Warner. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No. 5, revised, Society of Nuclear Medicine, New York (1978).
21. J.P. Segars. Development and Application of the New Dynamic NURBS-based Cardiac-Torso (NCAT) Phantom, Ph.D. Dissertation, The University of North Carolina (2001).
22. M. G. Stabin, R. B. Sparks, E. Crowe. OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med 46 1023-1027 (2005).
23. M. Cristy and K. Eckerman. Specific absorbed fractions of energy at various ages from internal photons sources. ORNL/TM-8381 V1-V7. Oak Ridge National Laboratory, Oak Ridge, TN (1987).
24. M. Stabin, E. Watson, M. Cristy, J. Ryman, K. Eckerman, J. Davis, D. Marshall., K. Gehlen. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. ORNL Report ORNL/TM-12907 (1995).
25. E.E. Watson, M.G. Stabin, J.L. Davis, K.F. Eckerman. A Model of the Peritoneal Cavity for Use in Internal Dosimetry. J Nucl Med 30:2002-2011 (1989).
26. M.G. Stabin. A Model of the Prostate Gland for Use in Internal Dosimetry. J Nucl Med 35(3):516-520 (1994).
27. L. Bouchet, W. Bolch, D. Weber, H. Atkins, J. Poston, Sr. MIRD Pamphlet No 15: Radionuclide S values in a revised dosimetric model of the adult head and brain. J Nucl Med 40:62S-101S (1999).
28. L.G. Bouchet, W.E. Bolch, H.P. Blanco, B.W. Wessels, J.A. Siegel, D.A. Rajon, I. Clairand, G. Sgouros. MIRD Pamphlet No. 19: Absorbed Fractions and Radionuclide S Values for Six Age-Dependent Multiregion Models of the Kidney. J Nucl. Med. 44: 1113-1147 (2003).
29. M.G. Stabin, M. Konijnenberg. Re-evaluation of absorbed fractions for photons and electrons in small spheres. J Nucl Med 41:149-160 (2000).
30. K.S. Kolbert, G. Sgouros, A.M. Scott, J.E. Bronstein, R.A. Malane, J. Zhang, H. Kalaigian, S. McNamara, L. Schwartz, S.M. Larson. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl. Med. 38: 301-308 (1997).
31. Y. K. Dewaraja, S.J. Wilderman, M. Ljungberg, K.F. Koral, K. Zasadny, M. S. Kaminiski. Accurate Dosimetry in 13 1I Radionuclide Therapy Using Patient-Specific, 3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation. J Nucl. Med. 2005 46: 840-849 (2005).
32. A. Liu, L. Williams, G. Lopatin, D. Yamauchi, J. Wong, A. Raubitschek. A radionuclide therapy treatment planning and dose estimation system. J Nucl Med 40:1151-1153 (1999).
33. M. J. Guy, G. D. Flux, P. Papavasileiou, M. A. Flower, R. J. Ott. RMDP: A dedicated package for I-131 SPECT quantification, registration and patient-specific dosimetry, Cancer Biotherapy and Radiopharmaceuticals, 18(1): 61-69, (2003).
34. I. Clairand, M. Ricard, J. Gouriou, M. Di Paola, B. Aubert. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl. Med. 40: 1517-1523 (1999).
35. J. Lehmann, C. Hartmann Siantar, D.E. Wessol, C.A. Wemple, D. Nigg, J. Cogliati, T. Daly, M.A. Descalle, T. Flickinger, D. Pletcher, G. Denardo. Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system. Phys Med Biol. Mar 7;50(5):947-58 (2005).
36. G. Sgouros, K.S. Kolbert, A.Sheikh, K.S. Pentlow, E.F. Mun, A.Barth, R.J. Robbins, S.M. Larson. Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software. J Nucl Med 45: 1366-1372, (2004).